| 15.8 0.12 (0.77%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.64 | 1-year : | 26.45 |
| Resists | First : | 19.38 | Second : | 22.64 |
| Pivot price | 11.44 |
|||
| Supports | First : | 12.53 | Second : | 8.28 |
| MAs | MA(5) : | 15.14 |
MA(20) : | 10.85 |
| MA(100) : | 6.62 |
MA(250) : | 5.75 |
|
| MACD | MACD : | 1.6 |
Signal : | 1 |
| %K %D | K(14,3) : | 73.7  |
D(3) : | 76.2 |
| RSI | RSI(14): 73.6 |
|||
| 52-week | High : | 19.38 | Low : | 1.91 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KOD ] has closed below upper band by 9.1%. Bollinger Bands are 290.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.52 - 16.58 | 16.58 - 16.65 |
| Low: | 14.89 - 14.96 | 14.96 - 15.04 |
| Close: | 15.68 - 15.79 | 15.79 - 15.91 |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Sat, 27 Sep 2025
Kodiak Sciences (NASDAQ:KOD) Raised to "Hold" at Wall Street Zen - MarketBeat
Thu, 25 Sep 2025
Kodiak Sciences (KOD) Upgraded by Barclays Following Positive Tr - GuruFocus
Thu, 25 Sep 2025
Kodiak Sciences stock surges after Barclays upgrade - Investing.com
Thu, 25 Sep 2025
Kodiak stock upgraded at Barclays on Roche data (KOD:NASDAQ) - Seeking Alpha
Thu, 25 Sep 2025
Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday - Benzinga
Thu, 25 Sep 2025
Kodiak Sciences (NASDAQ:KOD) Shares Gap Up on Analyst Upgrade - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 79.2 (%) |
| Shares Short | 2,910 (K) |
| Shares Short P.Month | 2,520 (K) |
| EPS | -3.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.4 % |
| Return on Equity (ttm) | -140.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -115 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -4.17 |
| PEG Ratio | 0 |
| Price to Book value | 11.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|